Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Pembrolizumab and Ipilimumab Following Initial Anti-PD1/L1 Antibody

NCT02743819 is registered in ClinicalTrials.gov with University of Chicago as lead sponsor.

NCT NCT02743819
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02743819 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Pembrolizumab and Ipilimumab Following Initial Anti-PD1/L1 Antibody
Lead sponsor
University of Chicago
Phase
Phase 2
Overall status
Active, not recruiting
Start date
June 28, 2016
Completion date
June 30, 2026
Enrollment
70 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma